prikaz prve stranice dokumenta Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study
  Download
PDF 137.35 KB
Scientific paper - Original scientific paper
Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study
Central European Journal of Immunology, 44 (2019), 1; 33-37. https://doi.org/10.5114/ceji.2019.84012
Marjanac, Igor; Lovrić, Robert; Barbić, Jerko

Cite this document

Marjanac, I., Lovrić, R. & Barbić, J. (2019). Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study. Central European Journal of Immunology, 44. (1), 33-37. doi: 10.5114/ceji.2019.84012

Marjanac, Igor, et al. "Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study." Central European Journal of Immunology, vol. 44, no. 1, 2019, pp. 33-37. https://doi.org/10.5114/ceji.2019.84012

Marjanac, Igor, Robert Lovrić and Jerko Barbić. "Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study." Central European Journal of Immunology 44, no. 1 (2019): 33-37. https://doi.org/10.5114/ceji.2019.84012

Marjanac, I., Lovrić, R. and Barbić, J. (2019) 'Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study', Central European Journal of Immunology, 44(1), pp. 33-37. doi: 10.5114/ceji.2019.84012

Marjanac I, Lovrić R, Barbić J. Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study. Central European Journal of Immunology [Internet]. 2019 [cited 2024 April 23];44(1):33-37. doi: 10.5114/ceji.2019.84012

I. Marjanac, R. Lovrić and J. Barbić, "Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study", Central European Journal of Immunology, vol. 44, no. 1, pp. 33-37, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:239:694084. [Accessed: 23 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Serum Levels of the High-mobility Group box 1 Protein (HMGB1) in Children with Type 1 Diabetes Mellitus: Case-control Study
AuthorIgor Marjanac
MBZ: 371805
AuthorRobert Lovrić
MBZ: 343885
AuthorJerko Barbić
MBZ: 258420
Author's institution(Clinical hospital center Osijek)
Author's institutionJosip Juraj Strossmayer University of Osijek
Faculty of Dental Medicine and Health Osijek
Author's institutionJosip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Clinical Immunology
Abstract (english)
INTRODUCTION: The involvement of the high-mobility group box 1 protein (HMGB1) in various autoimmune and inflammatory diseases has been documented; however, the role of this proinflammatory molecule in children with diabetes type 1 (T1DM) has not been addressed. The aim of this case-control study is to compare the serum level of HMGB1 in children with newly diagnosed T1DM (group 1) and a control group composed of healthy children. MATERIAL AND METHODS: This case-control study included 136 children: group 1 (n = 96) and a control group (n = 40). Measurements were taken from serum for the following: HMGB1, white blood cell count, C-reactive protein, glucose, haemoglobin A1C, and β-cell autoantibodies (GADA-65, IA-2, ICA). HMGB1 was determined using enzyme-linked immunosorbent assay on a Labsystems iEMS Reader MF analyser (Labsystems Diagnostics Oy, Helsinki, Finland). RESULTS: The level (median and interquartile range) of HMGB1 was statistically higher (p < 0.001) in children with T1DM: 8.7 (5.0-9.8) µg/l, in comparison with the control group: 1.0 (0.6-1.4) µg/l. No correlation was found between HMGB1 and HbA1c in group 1, or between HMGB1 and BMI. A statistically higher percentage of positive children for autoantibodies were present in group 1 compared to the control group (p ≤ 0.001). HMGB1 serum levels were also tested and the presence of autoantibodies, and none of those antibodies correlated with the level of HMGB1. CONCLUSIONS: The higher level of HMGB1 in children with T1DM, compared to the control group, indicates that this proinflammatory molecule is a good candidate marker of inflammation in children with T1DM.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleCentral European Journal of Immunology
Numberingvol. 44, no. 1, pp. 33-37
p-ISSN1426-3912
e-ISSN1644-4124
DOIhttps://doi.org/10.5114/ceji.2019.84012
URN:NBNurn:nbn:hr:239:694084
Publication2019
Document URLhttp://europepmc.org/abstract/MED/31114434
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) icon
Created on2019-11-28 08:51:00